U.S. Great Health Completes Acquisition of 100% Equity of Ci Ming Medical Examination
On July 12, the US Great Health Announced that it had received a notice from the China Securities Regulatory Commission recently, and was reviewed by the China Securities Regulatory Commission's M&A Audit Committee on July 12, 2017 at the 40th Working Meeting held on July 12, 2017. , Mid-Autumn Health issued shares and paid cash to purchase assets and raise matching funds and related transactions were unconditionally passed.
According to the "Announcement on Adjusting the Issuance of Shares to Purchase Assets and Raising the Matching Funds and Related Party Transaction Plan" issued by the US Health Care, the transaction refers to the plan to purchase the shares in the form of non-public issuance of shares and payment of cash. A total of 72.22% of the shares of Ciming Medical Insurance held by five shareholders including Yizi Management. According to the announcement, the transaction price of 72.22% equity of Ciming Medical Examination was 2.697 billion yuan, and Mei Nian Health intends to pay by way of non-public issuance of 150,765,381 shares and cash payment of 350 million yuan. Upon completion of this transaction, Ciming Medical Examination will become a wholly-owned subsidiary of Mei Nian Health.
The actual net profit of Ciming Medical Examination in 2016 was 124 million yuan, a year-on-year increase of 21.51%. In the profit forecast, Midyear Health said that compared with the compound growth rate of 46.77% of the three-year healthy income of the US, the compound growth rate of net profit of 61.22%, the profitability of Ciming’s medical examination is still comparable. Great room for improvement.
According to Caixin.com, Ci Ming’s top executives will focus on other health-related businesses. This is an idea that has been in existence for a long time. At the same time, due to the prohibition of the industry, they will not continue to do the medical examination business, but to do related downstream products. Including pre-pregnancy testing, medical big data, and investment in the medical field. According to the plan of the US Health Year, after the acquisition of Ci Ming, the US Health and Ciming Medical Examination will be called the two subsidiaries of the listed company respectively, with their respective boards of directors in their respective management teams, sales, finance, manpower, etc. Keep each other independent. In the future, the two major brands will also develop in a differentiated way: on the basis of consolidating the original advantageous areas, the focus of the development layout will be on the sinking of the third- and fourth-tier cities; Continue to consolidate and enhance the advantages of traditional areas such as Beijing.
Antitumor And Chemotherapy Antiemetic
Antitumor And Chemotherapy Antiemetic,Tropisetron Hydrochloride Tablets,Tablets Of Tropisetron Hydrochloride,Tablets For Antitumor And Antiemetic
Shandong Qidu Pharmaceutical Co., Ltd. , https://www.qdyypharma.com